Dyspepsia in Medical Technology
Navigation Links
Dyspepsia in Medical Technology
... vs 5%-7%),
constipation (8%- 10% vs 3%-4%), SGPT increase (5% vs 1%), dyspepsia (5%-7%
vs 1%-4%), lethargy (5% vs 2%), and weight gain (5% vs 1%). The ... for schizophrenia were dry
mouth (12% vs 1%), constipation (6% vs 5%), dyspepsia (5% vs 2%), sedation
(13% vs 7%), somnolence (12% vs 4%), dizziness (10% ...
... in the PHIRST-1 clinical trial were headache, myalgia, nasopharyngitis, flushing, respiratory tract infection, extremity pain, nausea, back pain, dyspepsia and nasal congestion. In rare instances, patients taking PDE5 inhibitors (including tadalafil) reported a sudden decrease or loss of vision or ...
... subjects) for lurasidone versus placebo were nausea (16% vs. 3%), headache (11.1% vs. 10%), constipation (11.1% vs. 5.6%), vomiting (11.1% vs. 5.6%), dyspepsia (11.1% vs. 3.3%), somnolence (11.1% vs. 3.3%), insomnia (10.0% vs. 3.3%) and sedation (10.0% vs. 4.4%). Lurasidone had a lower overall ...
... 2 and 38% vs. 16% in CAPACITY 1), rash (31% vs. 10% and 34% vs. 13%), fatigue (28% vs. 21% and 33% vs. 20%), diarrhea (25% vs. 17% and 33% vs. 21%), dyspepsia (17% vs. 9% and 21% vs. 6%), and dizziness (19% vs. 10% and 18% vs. 10%). Rash was generally mild to moderate in both studies; only 2 patients (1 in ...
... with 5 points in the placebo group. Tadalafil 5 mg was generally well-tolerated, and the most frequently reported adverse events were headache, dyspepsia and nasal congestion. Three subjects in the tadalafil group discontinued their participation in the study due to adverse events. About Cialis ...
... (13% vs 4%), bronchitis (13% vs 8%), hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), hypotension (12% vs 3%), dyspepsia (11% vs 7%), nasopharyngitis (11% vs 8%), bone pain (11% vs 10%), arthralgia (11% vs 15%) and pruritus (10% vs 5%). About Millennium ...
... (13% vs 4%), bronchitis (13% vs 8%), hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), hypotension (12% vs 3%), dyspepsia (11% vs 7%), nasopharyngitis (11% vs 8%), bone pain (11% vs 10%), arthralgia (11% vs 15%) and pruritus (10% vs 5%). About Millennium ...
... (14 percent, 2 percent), Pain in Extremity (13 percent, 5 percent) , Abdominal Pain (11 percent, 0 percent), Shoulder Pain (8 percent, 0 percent), dyspepsia (7 percent, 0 percent), and Paresthesia (6 percent, 0 percent). -- As with all therapeutic proteins, patients may develop antibodies to the ...
... (13% vs 4%), bronchitis (13% vs 8%), hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), hypotension (12% vs 3%), dyspepsia (11% vs 7%), nasopharyngitis (11% vs 8%), bone pain (11% vs 10%), arthralgia (11% vs 15%) and pruritus (10% vs 5%). About Millennium ...
... abdominal pain (5 percent), rash (6 percent), vomiting (4 percent), asthenia (3 percent), headache (2 percent), abdominal distension (2 percent), and dyspepsia (2 percent). This is not a complete list of all adverse drug reactions reported with the use of PREZISTA/r. Please see full Prescribing ...
... age, previous history of ulcers or bleeding, presence of H. pylori (a common bacteria that contributes to the development of stomach ulcers), dyspepsia or GERD (gastroesophageal reflux disease or "acid reflux") symptoms, as well as the simultaneous use of NSAIDs, anticoagulants and/or ....
... (13% vs 4%), bronchitis (13% vs 8%), hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), hypotension (12% vs 3%), dyspepsia (11% vs 7%), nasopharyngitis (11% vs 8%), bone pain (11% vs 10%), arthralgia (11% vs 15%) and pruritus (10% vs 5%). Important Safety Information ...
... of patients -- and more commonly with Welchol than placebo -- regardless of investigator assessment of causality were constipation (11.0% vs. 7.0%), dyspepsia (8.3% vs. 3.5%), nausea (4.2% vs. 3.9%), accidental injury (3.7% vs. 2.7%), asthenia (3.6% vs. 1.9%), pharyngitis (3.2% vs. 1.9%), flu syndrome (3.2% ...
... of patients - and more commonly with Welchol than placebo -- regardless of investigator assessment of causality were constipation (11.0% vs. 7.0%), dyspepsia (8.3% vs. 3.5%), nausea (4.2% vs. 3.9%), accidental injury (3.7% vs. 2.7%), asthenia (3.6% vs. 1.9%), pharyngitis (3.2% vs. 1.9%), flu syndrome (3.2% ...
... associated with the use of SEROQUEL XR versus placebo in clinical trials for schizophrenia were dry mouth (12% vs 1%), constipation (6% vs 5%), dyspepsia (5% vs 2%), sedation (13% vs 7%), somnolence (12% vs 4%), dizziness (10% vs 4%), and orthostatic hypotension (7% vs 5%). In long-term clinical ...
... associated with the use of SEROQUEL XR versus placebo in clinical trials for schizophrenia were dry mouth (12% vs 1%), constipation (6% vs 5%), dyspepsia (5% vs 2%), sedation (13% vs 7%), somnolence (12% vs 4%), dizziness (10% vs 4%), and orthostatic hypotension (7% vs 5%). In long-term clinical ...
... 4-week treatment period, were headache, injection site reaction, myalgia, fatigue, chills, rash, nausea, diarrhea, arthralgia, pyrexia, dizziness, dyspepsia and pruritis. The frequency and severity of these adverse events, as well as any general body system observations, were generally similar to ...
... of patients -- and more commonly with Welchol than placebo -- regardless of investigator assessment of causality were constipation (11.0% vs. 7.0%), dyspepsia (8.3% vs. 3.5%), nausea (4.2% vs. 3.9%), accidental injury (3.7% vs. 2.7%), asthenia (3.6% vs. 1.9%), pharyngitis (3.2% vs. 1.9%), flu syndrome (3.2% ...
... with once-monthly Boniva regardless of causality were abdominal pain (Boniva 150 mg 7.8% vs. Boniva 2.5 mg 5.3%), hypertension (6.3% vs. 7.3%), dyspepsia (5.6% vs. 7.1%), arthralgia (5.6% vs. 3.5%), nausea (5.1% vs. 4.8%) and diarrhea (5.1% vs. 4.1%). For complete prescribing information for Boniva, ...
... regimens were similar. The most commonly reported adverse events regardless of causality were arthralgia (Actonel 75 mg 10.4% vs Actonel 5 mg 9.5%), dyspepsia (9.1% vs 7.3%), and back pain (8.8% vs 10.8%). Please see full prescribing information for Actonel(R) (risedronate sodium tablets) for additional ...
... muscle cramps, skin rash, vomiting, diarrhea, abdominal pain, myalgia, arthralgia, hemorrhage, fatigue, headache, joint pain, cough, dizziness, dyspepsia and dyspnea, dermatitis, eczema, fluid retention, as well as neutropenia, thrombocytopenia and anemia. Glivec was generally well-tolerated in all of ...
... (20% vs 17%), insomnia (19% vs 14%), nausea (16% vs 12%), vomiting (12% vs 6%), dizziness (11% vs 8%), constipation (11% vs 7%), dyspepsia (10% vs 8%), and akathisia (10% vs 4%). Aripiprazole Injection In short-term (24 hour) trials, the following were reported ...
... vs 3-13%), sedation (30% vs 8%), somnolence (18-28% vs 7-8%), dizziness (11-18% vs 5-7%), constipation (8-10% vs 3-4%), SGPT increase (5% vs 1%), dyspepsia (5-7% vs 1-4%), lethargy (5% vs 2%), and weight gain (5% vs 1%). The most commonly observed adverse events associated with the use of SEROQUEL versus ...
... fever, pain, mucous membrane disorder, back pain, infection, headache, nausea, stomatitis (mouth sores), vomiting, constipation, diarrhea, anorexia, dyspepsia (indigestion), intestinal obstruction, peripheral edema (foot, leg, and/or ankle swelling), paresthesia (sensation of tingling, pricking, or numbness ...
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
... vs 5%-7%), constipation (8%- 10% vs 3%-4%), SGPT increase (5% vs 1%), dyspepsia (5%-7% vs 1%-4%), lethargy (5% vs 2%), and weight gain (5% vs 1%). The ... for schizophrenia were dry mouth (12% vs 1%), constipation (6% vs 5%), dyspepsia (5% vs 2%), sedation (13% vs 7%), somnolence (12% vs 4%), dizziness (10% ...... in the PHIRST-1 clinical trial were headache, myalgia, nasopharyngitis, flushing, respiratory tract infection, extremity pain, nausea, back pain, dyspepsia and nasal congestion. In rare instances, patients taking PDE5 inhibitors (including tadalafil) reported a sudden decrease or loss of vision or ...
... subjects) for lurasidone versus placebo were nausea (16% vs. 3%), headache (11.1% vs. 10%), constipation (11.1% vs. 5.6%), vomiting (11.1% vs. 5.6%), dyspepsia (11.1% vs. 3.3%), somnolence (11.1% vs. 3.3%), insomnia (10.0% vs. 3.3%) and sedation (10.0% vs. 4.4%). Lurasidone had a lower overall ...
FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
... in the PHIRST-1 clinical trial were headache, myalgia, nasopharyngitis, flushing, respiratory tract infection, extremity pain, nausea, back pain, dyspepsia and nasal congestion. In rare instances, patients taking PDE5 inhibitors (including tadalafil) reported a sudden decrease or loss of vision or ...... 2 and 38% vs. 16% in CAPACITY 1), rash (31% vs. 10% and 34% vs. 13%), fatigue (28% vs. 21% and 33% vs. 20%), diarrhea (25% vs. 17% and 33% vs. 21%), dyspepsia (17% vs. 9% and 21% vs. 6%), and dizziness (19% vs. 10% and 18% vs. 10%). Rash was generally mild to moderate in both studies; only 2 patients (1 in ...
... with 5 points in the placebo group. Tadalafil 5 mg was generally well-tolerated, and the most frequently reported adverse events were headache, dyspepsia and nasal congestion. Three subjects in the tadalafil group discontinued their participation in the study due to adverse events. About Cialis ...
... (13% vs 4%), bronchitis (13% vs 8%), hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), hypotension (12% vs 3%), dyspepsia (11% vs 7%), nasopharyngitis (11% vs 8%), bone pain (11% vs 10%), arthralgia (11% vs 15%) and pruritus (10% vs 5%). About Millennium ...
... (13% vs 4%), bronchitis (13% vs 8%), hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), hypotension (12% vs 3%), dyspepsia (11% vs 7%), nasopharyngitis (11% vs 8%), bone pain (11% vs 10%), arthralgia (11% vs 15%) and pruritus (10% vs 5%). About Millennium ...
... (14 percent, 2 percent), Pain in Extremity (13 percent, 5 percent) , Abdominal Pain (11 percent, 0 percent), Shoulder Pain (8 percent, 0 percent), dyspepsia (7 percent, 0 percent), and Paresthesia (6 percent, 0 percent). -- As with all therapeutic proteins, patients may develop antibodies to the ...
... (13% vs 4%), bronchitis (13% vs 8%), hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), hypotension (12% vs 3%), dyspepsia (11% vs 7%), nasopharyngitis (11% vs 8%), bone pain (11% vs 10%), arthralgia (11% vs 15%) and pruritus (10% vs 5%). About Millennium ...
... abdominal pain (5 percent), rash (6 percent), vomiting (4 percent), asthenia (3 percent), headache (2 percent), abdominal distension (2 percent), and dyspepsia (2 percent). This is not a complete list of all adverse drug reactions reported with the use of PREZISTA/r. Please see full Prescribing ...
... age, previous history of ulcers or bleeding, presence of H. pylori (a common bacteria that contributes to the development of stomach ulcers), dyspepsia or GERD (gastroesophageal reflux disease or "acid reflux") symptoms, as well as the simultaneous use of NSAIDs, anticoagulants and/or ....
... (13% vs 4%), bronchitis (13% vs 8%), hypokalemia (13% vs 7%), hypertension (13% vs 7%), abdominal pain upper (12% vs 9%), hypotension (12% vs 3%), dyspepsia (11% vs 7%), nasopharyngitis (11% vs 8%), bone pain (11% vs 10%), arthralgia (11% vs 15%) and pruritus (10% vs 5%). Important Safety Information ...
... of patients -- and more commonly with Welchol than placebo -- regardless of investigator assessment of causality were constipation (11.0% vs. 7.0%), dyspepsia (8.3% vs. 3.5%), nausea (4.2% vs. 3.9%), accidental injury (3.7% vs. 2.7%), asthenia (3.6% vs. 1.9%), pharyngitis (3.2% vs. 1.9%), flu syndrome (3.2% ...
... of patients - and more commonly with Welchol than placebo -- regardless of investigator assessment of causality were constipation (11.0% vs. 7.0%), dyspepsia (8.3% vs. 3.5%), nausea (4.2% vs. 3.9%), accidental injury (3.7% vs. 2.7%), asthenia (3.6% vs. 1.9%), pharyngitis (3.2% vs. 1.9%), flu syndrome (3.2% ...
... associated with the use of SEROQUEL XR versus placebo in clinical trials for schizophrenia were dry mouth (12% vs 1%), constipation (6% vs 5%), dyspepsia (5% vs 2%), sedation (13% vs 7%), somnolence (12% vs 4%), dizziness (10% vs 4%), and orthostatic hypotension (7% vs 5%). In long-term clinical ...
... associated with the use of SEROQUEL XR versus placebo in clinical trials for schizophrenia were dry mouth (12% vs 1%), constipation (6% vs 5%), dyspepsia (5% vs 2%), sedation (13% vs 7%), somnolence (12% vs 4%), dizziness (10% vs 4%), and orthostatic hypotension (7% vs 5%). In long-term clinical ...
... 4-week treatment period, were headache, injection site reaction, myalgia, fatigue, chills, rash, nausea, diarrhea, arthralgia, pyrexia, dizziness, dyspepsia and pruritis. The frequency and severity of these adverse events, as well as any general body system observations, were generally similar to ...
... of patients -- and more commonly with Welchol than placebo -- regardless of investigator assessment of causality were constipation (11.0% vs. 7.0%), dyspepsia (8.3% vs. 3.5%), nausea (4.2% vs. 3.9%), accidental injury (3.7% vs. 2.7%), asthenia (3.6% vs. 1.9%), pharyngitis (3.2% vs. 1.9%), flu syndrome (3.2% ...
... with once-monthly Boniva regardless of causality were abdominal pain (Boniva 150 mg 7.8% vs. Boniva 2.5 mg 5.3%), hypertension (6.3% vs. 7.3%), dyspepsia (5.6% vs. 7.1%), arthralgia (5.6% vs. 3.5%), nausea (5.1% vs. 4.8%) and diarrhea (5.1% vs. 4.1%). For complete prescribing information for Boniva, ...
... regimens were similar. The most commonly reported adverse events regardless of causality were arthralgia (Actonel 75 mg 10.4% vs Actonel 5 mg 9.5%), dyspepsia (9.1% vs 7.3%), and back pain (8.8% vs 10.8%). Please see full prescribing information for Actonel(R) (risedronate sodium tablets) for additional ...
Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data Published in JAMA
... (5 percent in Study 1; 3 percent in Study 2), somnolence (3 percent/4 percent), nausea (3 percent/4 percent) and paresthesia (3 percent/2 percent), dyspepsia (3 percent in Study 2 only), dry mouth (2 percent/2 percent) and chest discomfort (2 percent in Study 1 only.) About Imitrex(R) (sumatriptan ...... muscle cramps, skin rash, vomiting, diarrhea, abdominal pain, myalgia, arthralgia, hemorrhage, fatigue, headache, joint pain, cough, dizziness, dyspepsia and dyspnea, dermatitis, eczema, fluid retention, as well as neutropenia, thrombocytopenia and anemia. Glivec was generally well-tolerated in all of ...
Alterations in Intestinal Serotonin in Irritable Bowel Syndrome and Dyspepsia
... were obtained from the stomach and intestines of each patient and serotonin levels were measured. Researchers found that patients with dyspepsia had low levels of a serotonin reuptake transporter in their stomachs and high levels of a molecule that synthesizes serotonin in the small intestine. ...... (20% vs 17%), insomnia (19% vs 14%), nausea (16% vs 12%), vomiting (12% vs 6%), dizziness (11% vs 8%), constipation (11% vs 7%), dyspepsia (10% vs 8%), and akathisia (10% vs 4%). Aripiprazole Injection In short-term (24 hour) trials, the following were reported ...
... vs 3-13%), sedation (30% vs 8%), somnolence (18-28% vs 7-8%), dizziness (11-18% vs 5-7%), constipation (8-10% vs 3-4%), SGPT increase (5% vs 1%), dyspepsia (5-7% vs 1-4%), lethargy (5% vs 2%), and weight gain (5% vs 1%). The most commonly observed adverse events associated with the use of SEROQUEL versus ...
Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
... anxiety (20% vs 17%), insomnia (19% vs 14%), nausea (16% vs 12%), vomiting (12% vs 6%), dizziness (11% vs 8%), constipation (11% vs 7%), dyspepsia (10% vs 8%), and akathisia (10% vs 4%). Aripiprazole Injection In short-term (24 hour) trials, the following were reported at an ...... fever, pain, mucous membrane disorder, back pain, infection, headache, nausea, stomatitis (mouth sores), vomiting, constipation, diarrhea, anorexia, dyspepsia (indigestion), intestinal obstruction, peripheral edema (foot, leg, and/or ankle swelling), paresthesia (sensation of tingling, pricking, or numbness ...
Dynogen Reports Positive Results in Phase 1B GERD Study
... the United States. Persistent heartburn is the most common symptom of GERD, but patients may also experience acid regurgitation into the esophagus, dyspepsia (stomach pain) and dysphagia (difficulty swallowing). GERD affects all age groups, although the incidence increases markedly after the age of 40. If ...Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study
... the United States. Persistent heartburn is the most common symptom of GERD, but patients may also experience acid regurgitation into the esophagus, dyspepsia (stomach pain) and dysphagia (difficulty swallowing). GERD affects all age groups, although the incidence increases markedly after the age of 40. ...Other ContentsgonococcalglycosylatedglycosylatedgroingroingonorrheagonorrheabumpsbumpsbumpsbumpsgooseOther TagsDieselSpeciallyMotionMotionMotionAbnormalities
(Date:12/4/2009)This release is available in German . , A new study of the Max Planck Institute for Biology of Ageing could help to understand the positive effect of dietary restriction on healthy ageing. Previou
(Date:12/3/2009)Our ability to learn new information and adapt to changes in our daily environment, as well as to retain lifelong memories, appears to lie in the minute junctions where nerve cells communicate, accord
(Date:12/3/2009)ALBUQUERQUE, N.M. Most scientists believe that staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing because many b
Breaking Biology News(10 mins):How nutrition affects healthy aging 2Lifelong memories linked to stable nerve connections 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 33SBio Inc Announces Results of Annual General Meeting 5580 1Psychiatric disorders and sexual trauma are associated with lower urinary tract symptoms 59785 1Psychiatric disorders and sexual trauma are associated with lower urinary tract symptoms 59785 2SURF CRUISE CUP 2009 59783 1SURF CRUISE CUP 2009 59783 2(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
Breaking Medicine News(10 mins):Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2[0] Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders[0] Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification[0] Distributor Announces New Applications for Wind Turbines [0] KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children[0] Statement from AAHSA CEO Larry Minnix on the Failure of the Thune Amendment
DisturbingBlossomingTaxotereDieselMasalaVandetanibSpeciallySrinagarGrosslyDiscreditedMozambiqueMotionStandardizedAbnormalities
Other Tagsembryos 2embryos 3embryos 4embryos 5embryos 6succeed 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |